- Home
- TBN vs STRO Comparison
TBN vs STRO Comparison
Compare TBN & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBN
- STRO
- Stock Information
- Founded
- TBN 2009
- STRO 2003
- Country
- TBN Australia
- STRO United States
- Employees
- TBN N/A
- STRO N/A
- Industry
- TBN
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TBN
- STRO Health Care
- Exchange
- TBN NYSE
- STRO Nasdaq
- Market Cap
- TBN 239.3M
- STRO 172.8M
- IPO Year
- TBN 2024
- STRO 2018
- Fundamental
- Price
- TBN $20.55
- STRO $1.95
- Analyst Decision
- TBN Buy
- STRO Strong Buy
- Analyst Count
- TBN 3
- STRO 7
- Target Price
- TBN $34.67
- STRO $12.14
- AVG Volume (30 Days)
- TBN 11.0K
- STRO 1.4M
- Earning Date
- TBN 01-15-2025
- STRO 11-13-2024
- Dividend Yield
- TBN N/A
- STRO N/A
- EPS Growth
- TBN N/A
- STRO N/A
- EPS
- TBN N/A
- STRO N/A
- Revenue
- TBN N/A
- STRO $160,955,000.00
- Revenue This Year
- TBN N/A
- STRO N/A
- Revenue Next Year
- TBN N/A
- STRO N/A
- P/E Ratio
- TBN N/A
- STRO N/A
- Revenue Growth
- TBN N/A
- STRO 230.90
- 52 Week Low
- TBN $15.75
- STRO $1.70
- 52 Week High
- TBN $25.99
- STRO $6.13
- Technical
- Relative Strength Index (RSI)
- TBN N/A
- STRO 37.11
- Support Level
- TBN N/A
- STRO $1.80
- Resistance Level
- TBN N/A
- STRO $2.01
- Average True Range (ATR)
- TBN 0.00
- STRO 0.16
- MACD
- TBN 0.00
- STRO 0.03
- Stochastic Oscillator
- TBN 0.00
- STRO 37.18
About TBN TAMBORAN RESOURCES CORPORATION
Tamboran Resources Corp is a gas company focused on supporting the Net Zero CO2 energy transition in Australia and Asia-Pacific through developing low CO2 unconventional gas resources in the Australian Northern Territory.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers.